{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:50:12Z","timestamp":1773661812135,"version":"3.50.1"},"reference-count":44,"publisher":"Hindawi Limited","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3494,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1742-1241.2006.00750.x","type":"journal-article","created":{"date-parts":[[2006,2,6]],"date-time":"2006-02-06T16:13:51Z","timestamp":1139242431000},"page":"462-470","source":"Crossref","is-referenced-by-count":15,"title":["New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma"],"prefix":"10.1155","volume":"60","author":[{"given":"A.","family":"Sciarra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Cardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Dattilo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Mariotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Di Monaco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Di Silverio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2006,2,6]]},"reference":[{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0344-0338(86)80043-7","article-title":"Peptide-hormone and serotonin-immuno-reactive cells in normal and hyperplastic glands","volume":"181","author":"Abrahamsson","year":"1986","journal-title":"Pathol Res Pract"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/(SICI)1097-0045(199602)28:2<98::AID-PROS4>3.0.CO;2-J","article-title":"Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model","volume":"28","author":"Bonkhoff","year":"1996","journal-title":"Prostate"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/BF02655955","article-title":"Zur frage der endokrinie der menschlichen vorsteherdruse","volume":"312","author":"Pretl","year":"1944","journal-title":"Virch Arch Path Anat"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB4|cit4","first-page":"729","article-title":"Age-related changes in the neuroendocrine (endocrine-paracrine) cell population and the serotonin content of the guinea pig prostate","volume":"57","author":"Di Sant'Agnese","year":"1987","journal-title":"Lab Invest"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF00193496","article-title":"Age-related distribution of endocrine cells in the humane prostate: a quantitative study","volume":"424","author":"Battaglia","year":"1994","journal-title":"Virchows Arch"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/(SICI)1097-0045(1996)6+<3::AID-PROS2>3.0.CO;2-T","article-title":"Neuroendocrine differentiation and hormone-refractory prostate cancer","volume":"6","author":"Abrahamsson","year":"1996","journal-title":"Prostate Suppl"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB7|cit7","first-page":"1967","article-title":"The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue","volume":"53","author":"Nakada","year":"1993","journal-title":"Cancer Res"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/17.5.303","article-title":"The cytochemistry and ultrastructure of polypeptide hormone-producing cells APUD series and the embryologic, physiologic and pathologic implications of the concept","volume":"17","author":"Pearse","year":"1969","journal-title":"J Histochem Cytochem"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0046-8177(95)90033-0","article-title":"Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells","volume":"26","author":"Bonkhoff","year":"1995","journal-title":"Hum Pathol"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/(SICI)1097-0045(1998)8+<14::AID-PROS3>3.0.CO;2-G","article-title":"Receptors for BPH growth factors are located in some neuroendocrine cells","volume":"8","author":"Iwamura","year":"1998","journal-title":"Prostate Suppl"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/(SICI)1097-0045(1998)8+<18::AID-PROS4>3.0.CO;2-C","article-title":"Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation and androgen receptor status","volume":"8","author":"Bonkhoff","year":"1998","journal-title":"Prostate Suppl"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/(SICI)1097-0045(19970501)31:2<110::AID-PROS6>3.0.CO;2-R","article-title":"Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate","volume":"31","author":"Angelsen","year":"1997","journal-title":"Prostate"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/(SICI)1098-2825(1998)12:1<20::AID-JCLA4>3.0.CO;2-N","article-title":"Serum chromogranin A: early detection of hormonal resistance in prostate cancer patients","volume":"12","author":"Wu","year":"1998","journal-title":"J Clin Lab Anal"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/S0022-5347(01)66261-X","article-title":"Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma","volume":"155","author":"Cussenot","year":"1996","journal-title":"J Urol"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/1097-0142(19920701)70:1+<254::AID-CNCR2820701312>3.0.CO;2-E","article-title":"Neuroendocrine differentiation in carcinoma of the prostate","volume":"70","author":"Di Sant'Agnese","year":"1992","journal-title":"Cancer"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/0046-8177(94)90169-4","article-title":"Multidirectional differentiation in the normal, hyperplastic and neoplastic human prostate. Simultaneous demonstration of cell specific epithelial markers","volume":"25","author":"Bonkhoff","year":"1994","journal-title":"Hum Pathol"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB17|cit17","first-page":"1724","article-title":"Immunohistochemical localization or parathyroid hormone-related protein in human prostate cancer","volume":"53","author":"Iwamura","year":"1993","journal-title":"Cancer Res"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB18|cit18","first-page":"616","article-title":"Bcl2 protooncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell","volume":"118","author":"Segal","year":"1994","journal-title":"Arch Pathol Lab Med"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB19|cit19","first-page":"6940","article-title":"Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer","volume":"52","author":"McDonnell","year":"1992","journal-title":"Cancer Res"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/BF00268938","article-title":"Do neuroendocrine cells in human prostate cancer express androgen receptor?","volume":"100","author":"Krijnen","year":"1993","journal-title":"Histochemistry"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/(SICI)1097-0045(20000101)42:1<34::AID-PROS5>3.0.CO;2-2","article-title":"Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines","volume":"42","author":"Jongsma","year":"2000","journal-title":"Prostate"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0022-5347(17)37793-5","article-title":"Elevated plasma chromogranin A concentrations in prostatic carcinoma","volume":"146","author":"Kadmon","year":"1991","journal-title":"J Urol"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00005392-199707000-00054","article-title":"The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy","volume":"158","author":"Krijnen","year":"1997","journal-title":"J Urol"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/(SICI)1097-0045(20000301)42:4<274::AID-PROS4>3.0.CO;2-R","article-title":"Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment","volume":"42","author":"Ahlgren","year":"2000","journal-title":"Prostate"},{"issue":"Suppl. 8","key":"10.1111\/j.1742-1241.2006.00750.x-BIB25|cit25","first-page":"53","article-title":"Serum concentrations and prostatic gene expression of chromogranin A and PSA in patients affected by prostate cancer and benign prostatic hyperplasia","volume":"23","author":"Monti","year":"2000","journal-title":"J Endocrinol Invest"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB26|cit26","volume-title":"TNM Klassification Maligner Tumoren","author":"UICC.","year":"1997"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/pros.10222","article-title":"Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma","volume":"55","author":"Sciarra","year":"2003","journal-title":"Prostate"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.urology.2003.10.043","article-title":"Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate cancer","volume":"63","author":"Sciarra","year":"2004","journal-title":"Urology"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB29|cit29","first-page":"251","volume-title":"3rd International Consultation on Prostate Cancer - Paris.","author":"Carroll","year":"2003:"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/jnci\/88.13.908","article-title":"Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells","volume":"88","author":"Robertson","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000475067","article-title":"The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic","volume":"28","author":"Robinson","year":"1995","journal-title":"Eur Urol"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0090-4295(99)00580-4","article-title":"Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study","volume":"55","author":"Hedlund","year":"2000","journal-title":"Urology"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB33|cit33","first-page":"175","article-title":"Transdermal estrogen therapy for advanced prostate cancer-forward to the past?","volume":"167","author":"Ockrim","year":"2002","journal-title":"J Urol"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB34|cit34","first-page":"286","volume-title":"Gastrointestinal Endocrinology.","author":"Newman","year":"1987:"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s002590100541","article-title":"Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands","volume":"28","author":"Reubi","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/annonc\/mdf142","article-title":"The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?","volume":"13","author":"Hejna","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1517\/13543784.11.2.283","article-title":"Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancer","volume":"11","author":"Koutsilieris","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/(SICI)1097-0045(20000101)42:1<34::AID-PROS5>3.0.CO;2-2","article-title":"Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines","volume":"42","author":"Jongsma","year":"2000","journal-title":"Prostate"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB39|cit39","first-page":"616","article-title":"BCl2 proto-oncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell","volume":"118","author":"Segal","year":"1994","journal-title":"Arch Pathol Lab Med"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1530\/eje.0.1460701","article-title":"New somatostatin analogs: will they fulfill old promises?","volume":"146","author":"Lamberts","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1078-1439(01)00173-9","article-title":"Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines","volume":"7","author":"Dizeyi","year":"2002","journal-title":"Urol Oncol"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1097\/01.ju.0000092480.71873.26","article-title":"Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin A in patients with androgen ablation refractory prostate cancer","volume":"170","author":"Di Silverio","year":"2003","journal-title":"J Urol"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.1210\/jcem.86.12.8119","article-title":"A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LH-RH analog in androgen ablation-refractory prostate cancer patients","volume":"86","author":"Koutsilieris","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2006.00750.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1046\/j.1464-410X.2003.03066.x","article-title":"Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable?","volume":"91","author":"Sciarra","year":"2003","journal-title":"BJU Int"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2006.00750.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2006.00750.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:06:07Z","timestamp":1643349967000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2006.00750.x"}},"subtitle":["NEUROENDOCRINE DIFFERENTIATION IN PROSTATE ADENOCARCINOMA"],"short-title":[],"issued":{"date-parts":[[2006,2,6]]},"references-count":44,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2006.00750.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2006,2,6]]}}}